I noted with interest your sparse coverage of the National Institute for Clinical Excellence's guidance on glycoprotein IIb/IIIa inhibitors.

I was amazed that there was no mention whatsoever of the advice on implantable cardioverter defibrillators issued on the same day. Both documents, especially the ICD guidance calling for a threefold increase in their use, raise important questions about resource allocation and implementation.

Given that both these interventions could help achieve national targets on coronary heart disease, the inherent issues are worthy of further analysis.

Richard Devereaux-Phillips Corporate affairs and reimbursement manager, UK and Ireland Medtronic